The study included bladder cancer, triple-negative breast cancer, hormone receptor-positive HER2-negative breast cancer (estrogen-receptor-positive, Erb-B2 receptor tyrosine kinase 2-negative) colorectal adenocarcinoma, head and neck squamous cell carcinoma, melanoma, and small cell lung cancer samples [72]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.